Advances in hematology, oncology, and blood and marrow transplantation (BMT) have transformed patient outcomes over the past two decades. However, alongside these achievements lies a persistent and often underappreciated threat—Invasive Fungal Infections (IFIs). Despite significant improvements in diagnostics and antifungal therapies, IFIs continue to contribute substantially to morbidity, mortality, prolonged hospitalization, and healthcare costs among immunocompromised patients. Fungal infections in patients with blood cancers and blood disorders are neither rare nor unpredictable. And yet they continue to be diagnosed too late, too often.What Happens To The Immune System During Treatment?The treatments that have transformed the outlook for leukemia, lymphoma, myeloma, and serious bone marrow disorders are genuinely remarkable. Intensive chemotherapy, bone marrow transplantation, and the newer targeted therapies have extended and saved lives in ways that were not imaginable a generation ago. But each of them does something to the immune system that creates a serious risk.Chemotherapy depletes neutrophils, the white blood cells specifically responsible for recognizing and destroying fungal organisms. A transplant requires conditioning that leaves patients with almost no immune defenses for an extended period. Prolonged neutropenia, mucosal barrier injury, corticosteroid exposure, graft-versus-host disease, and the increasing use of targeted therapies collectively create an environment where opportunistic fungal pathogens can thrive. Some of the most effective modern therapies in hematology work by modifying immune pathways, leaving patients vulnerable to fungal disease for months after treatment ends. This window can last weeks, sometimes much longer.The Fungi That Exploit This WindowAspergillus is a mould found in ordinary dust and soil. In most people, it causes no harm whatsoever. In a patient with severely depleted white blood cells, it can establish a lung infection that progresses faster than most people would expect and carries a mortality rate that remains unacceptably high even with treatment. The earlier it is identified, the better the outcome. But the gap between early and late diagnosis in this context is narrow and unforgiving.Mucormycosis is less familiar to the public but arguably more aggressive. It invades blood vessel walls directly, cutting off blood supply to surrounding tissue. Patients with blood disorders who require repeated transfusions are at particular risk because excess iron in the body accelerates their growth significantly. India has the highest burden of this infection in the world. That statistic deserves more attention than it currently receives.Candida lives in the gut of most healthy individuals without causing any problems. When the gut lining is damaged by chemotherapy, it can cross into the bloodstream and reach the liver, spleen, and other organs, causing infections that are difficult to detect and slow to resolve.Delayed recognition frequently results in disease progression, leading to respiratory failure, disseminated infection, and poor outcomes.The Problem Is UnderdiagnosesNone of these infections begins dramatically. The early signs are a fever that does not settle with antibiotics, a cough without an obvious cause, and breathlessness that seems proportionate to the treatment but lingers too long. Ina patient already unwell from intensive therapy, these signs often get attributed to other causes. Time passes, and the infection progresses.Specific blood tests can indicate a fungal diagnosis before imaging shows anything definitive. They are not available everywhere in India, and that gap costs lives. Apart from the economic burden of IFIs, it can disrupt cancer treatment schedules, delaying chemotherapy or transplantation and potentially compromising long-term disease control.What Families Should KnowPreventive antifungal therapy for high-risk patients has strong evidence behind it. Centers that have built awareness of fungal infection risk into their standard care protocols consistently see better outcomes.For families, the most important thing is simply knowing this risk exists. Asking about it is entirely reasonable. Expecting it to be actively managed is also reasonable. In hematology and oncology, the infections that go unrecognised are the ones that do most of the damage.Invasive fungal infections are not merely infectious complications; they are major determinants of outcomes in modern hematology and oncology practice. Recognizing the hidden burden of IFIs is the first step toward reducing their impact and improving outcomes for our most vulnerable patients.